Sooyeon Kwon, PharmD, PhD

Expect more treatment options as new understandings about SLE’s pathogenesis emerge.

A review of current and emerging therapeutics – and how they work.

Even when a patient achieves low disease activity in RA, there can be problems with JAK inhibitors, routine vaccines, and lipid abnormalities.

Dr. Sooyeon Kwon explains how clinicians and community pharmacists can improve patient outcomes by counseling on the risks of biologic DMARDs and the importance of symptom monitoring.

Gene targets for treating rheumatoid arthritis, including inflammatory cytokines and matrix-degrading enzymes, and the latest evidence on TNF, IL, and JAK inhibitors for RA.

A review of new oral JAK inhibitor medications for the treatment of refractory rheumatoid arthritis and psoriatic arthritis, including tofacitinib (Xeljanz, Pfizer), baricitinib (Olumiant, Lilly), upadacitinib (Rinvoq, AbbVie), and filgotinib (GLPG0634, Gilead).